No Data
No Data
AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts
Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $250
AbbVie Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and AbbVie (ABBV)
Raymond James Adjusts Price Target on AbbVie to $227 From $220, Maintains Outperform Rating
Citi Sticks to Its Buy Rating for AbbVie (ABBV)
MOHD NOR B ABDULLAH : ok
74128907 :![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)